When the SARS epidemic was circling the globe, the World Health Organization (WHO) purported to be leading efforts to treat the disease. But the WHO was reluctant to send staffers to Taiwan, hard-hit due to its extensive ties with China.
For the WHO, politics was more important than health. Tai-pei is not a member of the WHO because most nations, including the US, formally consider it to be part of China. And Beijing objected to any WHO teams traveling to Taiwan. With no thanks to the WHO or Beijing, Taiwan avoided a disastrous outbreak.
Unfortunately, like most UN agencies, the WHO's activities have long been captive to a highly political agenda. For instance, earlier this year the organization claimed that a third of childhood deaths in Europe resulted from environmental causes.
It's a preposterous assertion. European analysts Jaap Hane-kamp and Julian Morris observe: "few of these deaths were actually caused by problems generally associated with `the environment.' Out of 100,000 total deaths, 75,000 were caused by accidents." The remainder, most in poorer countries such as Russia and Turkey, largely resulted from problems like malaria, poor sanitation and dirty water.
But the facts didn't stop the WHO. It was particularly upset about the presumed threat of global warming, which, it claimed, would result in "more widespread and severe" deaths.
Yet, Hanekamp and Morris archly observe, "No scientific evidence was offered to support these claims -- perhaps because none exists."
Nevertheless, the WHO is advancing its so-called Children's Environment and Health Action Plan for Europe which proposes more regulations over technology, such as fossil fuels, pesticides and plastics. The result would make us all poorer, yet wealthier societies are better able to prevent and treat illness.
For instance, the pesticide DDT is one of the most effective means to kill mosquitoes, which spread malaria. Important medical devices are made from plastics. The WHO is ignoring problems that today kill millions while fretting over worst-case scenarios for the future that are unlikely ever to occur.
Simply providing clean water and improving sanitation would do more to help Third World peoples than would most of the WHO's highly-publicized initiatives.
The organization has advanced the "Roll Back Malaria" program, along with UNICEF, the World Bank and the US Agency for International Development. Unlike global warming, malaria does kill. Yet the WHO has been distributing two drugs which are no longer effective in Africa.
Moreover, complain health-care analysts Robert Bate of the UK and Richard Tren, a South African, "Roll Back Malaria partners are unwilling to fund interventions that work but upset environ-mentalists, such as indoor insecticide spraying." It was widespread outdoor use of DDT years ago that had adverse environmental con-sequences; poor nations throughout Africa and South Asia are begging for help to undertake carefully targeted use indoors.
It's hard to know if anyone died because the WHO kowtowed to Beijing rather than cooperating with Taipei. Failing to fund effective anti-malaria measures does kill. Equally important, organization missteps involving the treatment of AIDS have harmed untold numbers of poor people in poor countries. The WHO actually has impeded distribution of effective medications.
Treating AIDS is one of the organization's primary responsibilities. Yet earlier this year the WHO was forced to remove foreign copies of patented AIDS drugs by the Indian firms Cipla and Ranbaxy from its list of pre-qualified medicines. This month Ranbaxy pulled its remaining seven antivirals from the WHO program.
As millions have suffered and died of HIV/AIDS, political activists worldwide have attacked the drugmakers. Yet without research-driven pharmaceutical companies, we would still live in the pre-1987 world, when there was no treatment for AIDS and the diagnosis was a death sentence.
Rather than pay for innovative new drugs, the WHO has promoted foreign knock-offs. Alas, the copies couldn't be certified as biologically equivalent or safe.
Thus, the WHO has endangered the very people it was supposed to be helping. The inadequate drugs risked encouraging the AIDS virus to mutate into strains resistant to all medicines. Moreover, diverting treatment dollars into inferior pharmaceuticals reduced the financial incentive for drug companies to develop newer and better products.
It's an appalling record, one of "Bad decisions, missed deadlines and bogus AIDS drugs," complains Waldemar Ingdahl, director of Eudoxa, a Swedish think tank: "Africans and the poor should not be treated with bad medicine."
The WHO has gone badly astray. Director-General Lee Jong-wook, chosen less than a year ago, must put good health before bad politics. Only then will the WHO live up to its promise, promoting health rather than harm.
Doug Bandow is a senior fellow at the Cato Institute and a former special assistant to the late US president Ronald Reagan.
KMT Chairwoman Cheng Li-wun’s (鄭麗文) recent visit to Beijing and her upcoming visit to Washington will serve as a high-level test of her diplomatic mettle. In Beijing, Cheng was received with symbolic gestures, a warm reception, and high-level access. In Washington, she will receive far less pomp and far sharper questions about the KMT’s vision for the future of Taiwan. Her challenge will be to persuade Washington that the KMT’s engagement with China can coexist with strong deterrence. Cheng’s April 7-12 visit to mainland China coincided with an intense period of conflict in Iran. Despite the strategic significance of Cheng’s trip,
The closure of the Strait of Hormuz has sent the vast Asian chemicals industry into a tailspin. Deprived of the likes of Qatari natural gas and Saudi Arabian oil, the region’s fertilizer and plastics plants are slowing production or even shutting down. Everywhere except China, that is. In petrochemicals, China is unique. As well as a traditional industry that uses oil and gas as feedstock, it has parallel output that relies on its abundant domestic coal. Unsurprisingly, India and other regional powers want to copy and paste the Chinese method. This would not be easy — or climate friendly. The
History might remember 2026, not 2022, as the year artificial intelligence (AI) truly changed everything. ChatGPT’s launch was a product moment. What is happening now is an anthropological moment: AI is no longer merely answering questions. It is now taking initiative and learning from others to get things done, behaving less like software and more like a colleague. The economic consequence is the rise of the one-person company — a structure anticipated in the 2024 book The Choices Amid Great Changes, which I coauthored. The real target of AI is not labor. It is hierarchy. When AI sharply reduces the cost
US President Donald Trump recently repeated his claim that “Taiwan stole America’s chip industry,” reigniting public debate on the issue. As a former Taiwanese minister of economic affairs and an entrepreneur deeply involved in semiconductor supply chain development, I feel a responsibility to clarify this misunderstanding. From the perspective of global industrial evolution and the economic principle of comparative advantage, such a statement appears overly simplistic and risks obscuring the essence of the issue. The rise of Taiwan’s semiconductor industry was not built on “replacing America,” but rather emerged as a result of countries pursuing different development paths within the